Personalized Hemodynamic Resuscitation Targeting Capillary Refill Time in Early Septic Shock: The ANDROMEDA-SHOCK-2 Randomized Clinical Trial

Personalized Hemodynamic Resuscitation Targeting Capillary Refill Time in Early Septic Shock: The ANDROMEDA-SHOCK-2 Randomized Clinical Trial

Personalized Hemodynamic Resuscitation Targeting Capillary Refill Time in Early Septic Shock: The ANDROMEDA-SHOCK-2 Randomized Clinical Trial.  Hernandez G, ANDROMEDA-SHOCK-2 Investigators for the ANDROMEDA Research Network JAMA. 2025 Oct 29:e2520402. doi:...
Acute Liver Failure

Acute Liver Failure

Acute Liver Failure (ALF) is rare, with an estimated incidence of 1–6 cases per million per year in Western countries¹². Despite its rarity, it carries significant morbidity and mortality¹. ALF most often affects previously healthy adults in their 30s; in North...
Tenecteplase versus standard medical treatment for basilar artery occlusion within 24 h (TRACE-5): a multicentre, prospective, randomised, open-label, blinded-endpoint, superiority, phase 3 trial.

Tenecteplase versus standard medical treatment for basilar artery occlusion within 24 h (TRACE-5): a multicentre, prospective, randomised, open-label, blinded-endpoint, superiority, phase 3 trial.

Tenecteplase versus standard medical treatment for basilar artery occlusion within 24 h (TRACE-5): a multicentre, prospective, randomised, open-label, blinded-endpoint, superiority, phase 3 trial Xiong Y, Et al. Lancet. 2026 Feb 21;407(10530):763-772. doi:...